LYRICA SUMMARY
LYRICA (pregabalin) binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin is unknown, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin) suggest that binding to the alpha2-delta subunit may be involved in pregabalin's antinociceptive and antiseizure effects in animal models. In vitro, pregabalin reduces the calcium-dependent release of several neurotransmitters, possibly by modulation of calcium channel function.
LYRICA is indicated for:
Management of neuropathic pain associated with diabetic peripheral neuropathy
Management of postherpetic neuralgia
Adjunctive therapy for adult patients with partial onset seizures
Management of fibromyalgia
|
NEWS HIGHLIGHTSMedia Articles Related to Lyrica (Pregabalin)
New Lyrica Oral Formulation For Patients With Dysphagia Available In UK
Source: Health News from Medical News Today [2012.05.11]
Lyrica® (pregabalin) is now available in a new strawberry-flavored oral solution form in the UK, in order to benefit patients who have difficulty in taking medication in capsule form or for those with dysphagia (swallowing difficulty). Pregabalin is licensed to treat peripheral and central neuropathic pain, generalized anxiety disorder (GAD) in adults as well as an adjunctive therapy for partial seizures with or without secondary generalization in adults...
Lyrica (pregabalin) No Good For Diabetes Or HIV Associated Neuropathic Pain
Source: Diabetes News From Medical News Today [2012.05.04]
Lyrica (pregabalin) failed in two separate human trials to reduce neuropathic pain linked to diabetes or HIV, said makers Pfizer today. One of the trials - Phase III HIV neuropathy - was stopped early because no benefits were found in an interim analysis on 246 patients out of a planned 416...
Lyrica Fails in Pain Trials
Source: MedPage Today Nephrology [2012.05.04]
(MedPage Today) -- Pregabalin (Lyrica) was not effective in reducing neuropathic pain associated with HIV infection or diabetes in two separate trials, the drug's manufacturer said.
Published Studies Related to Lyrica (Pregabalin)
An International, Randomized, Double-blind, Placebo-controlled, Phase III Trial of Pregabalin Monotherapy in Treatment of Patients with Fibromyalgia. [2011.12]
OBJECTIVE: To evaluate the efficacy and safety of pregabalin monotherapy versus placebo for symptomatic pain relief and improvement of patient global assessment in patients with fibromyalgia (FM) enrolled from countries outside the United States... CONCLUSION: Pregabalin demonstrated modest efficacy in pain, global assessment, and function in FM at 450 mg/day, and improved sleep across all dose levels, but it did not provide consistent evidence of benefit at 300 and 600 mg/day in this study. Pregabalin was generally well tolerated for the treatment of FM. (Clinical trial registry NCT00333866).
Pregabalin for the Treatment of Abdominal Adhesion Pain: A Randomized, Double-Blind, Placebo-Controlled Trial. [2011.10.17]
Chronic pain related to postoperative abdominal adhesions is a common problem with no standard analgesic regimen currently established. In a double-blind, placebo-controlled trial, we examined the effects of pregabalin on pain modulation in patients with prior abdominal surgery and documented adhesion...
Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. [2011.10]
BACKGROUND: Efficacious and safe monotherapy options are needed for adult patients with newly diagnosed epilepsy. As an adjunctive treatment for partial seizures, pregabalin compares favourably with lamotrigine and is an effective, approved treatment. We studied the efficacy and safety of pregabalin as monotherapy, using a design that complied with European regulatory requirements and International League Against Epilepsy guidelines... INTERPRETATION: Pregabalin has similar tolerability but seems to have inferior efficacy to lamotrigine for the treatment of newly diagnosed partial seizures in adults. Inferior efficacy of pregabalin might have been attributable to limitations in the study design, as treatment doses might have not been optimised adequately or early enough. FUNDING: Pfizer Inc. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. [2011.08]
BACKGROUND & AIMS: Pain is a disabling symptom for patients with chronic pancreatitis (CP) and difficult to treat. Evidence from basic science and human studies indicates that pain processing by the central nervous system is abnormal and resembles that observed in patients with neuropathic pain disorders. We investigated whether agents used to treat patients with neuropathic pain are effective in CP... CONCLUSIONS: In a placebo-controlled trial, pregabalin is an effective adjuvant therapy for pain in patients with CP. Copyright (c) 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
Effect of the alpha2delta ligand, pregabalin, on colonic sensory and motor functions in healthy adults. [2011.08]
Pregabalin, an alpha2delta ligand, is used clinically to treat somatic pain. A prior study suggested that pregabalin reduces distension-induced pain while increasing rectal compliance.Thus 200 mg of pregabalin reduces gas and pain sensation and should be tested in patients with colonic pain.
Clinical Trials Related to Lyrica (Pregabalin)
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures [Recruiting]
This study will determine the safety and efficacy of pregabalin (Lyrica) when administered
by itself (without any other anti-epileptic medication) to epilepsy subjects for the
treatment of partial seizures. The duration of the trial is about 6 months.
Pregabalin and Orofacial Neuropathic Pain [Recruiting]
The purpose of this study is to determine whether pregabalin can decrease pain and improve
quality of life in patients who have nerve pain on the mouth or the face
A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome [Recruiting]
This study is being done to see if Lyrica helps people with irritable bowel syndrome,
otherwise known as "IBS". Lyrica is the trade name for pregabalin, which was first approved
by the FDA in June 2005 and has been available through prescription since fall 2005, and is
marketed by Pfizer. Lyrica is known to have clinical efficacy treating pain disorders
including IBS-related conditions such as fibromyalgia.
A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder [Recruiting]
This study will examine the efficacy of pregabalin (Lyrica) added to SRI treatment in OCD
for individuals who have not responded or only partially responded to an adequate trial of
SRI. Although SRIs have demonstrated efficacy in OCD in numerous placebo-controlled trials,
response rates have been as low as 40%. Augmentation strategies would be beneficial to
maximize treatment response in OCD.
Pregabalin (Lyrica) is an anticonvulsant medication that appears to have a novel mechanism
of action. It has been shown to enhance activity at gamma-amino-butyric acid (GABA)
receptors as well as inhibit glutamate release. These two neurotransmitters systems have
been implicated in the neurobiology of OCD.
The study will consist of patients who have not attained full response to an SRI. The
patients will be randomized in a double-blind fashion to augmentation with pregabalin
(Lyrica) or placebo. The dose of study medication will be flexible, starting at 75 mg/day
and increasing in 75 mg increments to a maximum of 600 mg/day, based on efficacy and any
side effects. Patients' response to treatment will be measured by the Yale-Brown
Obsessive-Compulsive Scale (Y-BOCS), the Montgomery Asberg Depression Rating Scale (MADRS),
and the Clinical Global Impression Scale(CGI).
Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder [Recruiting]
The purpose of this study is to characterize the safety and efficacy in patients with
generalized anxiety disorder after short- (3 months) and long-term (6 months) use of
Pregabalin (Lyrica).
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 30 ratings/reviews, Lyrica has an overall score of 5.80. The effectiveness score is 6.73 and the side effect score is 5.67. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
| | Lyrica review by 46 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | Fibromyalgia |
| Dosage & duration: | | 150mg taken 2x per day for the period of Still taking it |
| Other conditions: | | None |
| Other drugs taken: | | None | | |
Reported Results |
| Benefits: | | Lyrica has made a huge difference with my fibromyalgia pain. I have had fibromyalgia for 13 plus years and was excited about the FDA finally approving Lyrica for fibromyalgia patients. I would recomend that anyone suffering from fibromyalgia try this medication, along with a healthy diet and exercise. Lyrica is not a cure, but I have improved probably 75% over this last year. |
| Side effects: | | It took my body 3-4 weeks to get used to Lyrica. It did make me feel a little different "high" would probably be the best way to describe it. I have since adjusted and have had no further side effects. |
| Comments: | | Started with 50 mg 2x a day (morning and afternoon), then gradually built up to 150mg 2x a day. |
|
| | Lyrica review by 63 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Considerably Effective |
| Side effects: | | Severe Side Effects | | |
Treatment Info |
| Condition / reason: | | fibromylgia |
| Dosage & duration: | | 5 0mg. taken 2 to 3 times day for the period of app. 4 yrs. |
| Other conditions: | | arthritis- asteproesis |
| Other drugs taken: | | zanaz- lorotab- pristiq | | |
Reported Results |
| Benefits: | | the benefits foe the pain was good, it helped the constant pain i was having in my muscles and the over all aching |
| Side effects: | | sleepiness- fatigu memory loss- confusion-depression- trouble breathigng |
| Comments: | | good relief from pain . i take 100mg. at bed time it helps me sleep well but am tired in the am. it makes me just want to lie on couch and sleep all day this makes my arthritis worse. am tired and draggy all day with no desire to do any thing, even the thing that have always interested me.am prescribed one 50g for daytimebut cannot tolerate it because i will sleep all day and be very light headed and unable to concentrate. |
|
| | Lyrica review by 58 year old female patient | | | Rating |
| Overall rating: | | |
| Effectiveness: | | Ineffective |
| Side effects: | | Severe Side Effects | | |
Treatment Info |
| Condition / reason: | | neuropathic pain aand fibromyalgia |
| Dosage & duration: | | 300mg/day taken 150mg twice/day for the period of 2 months |
| Other conditions: | | severe spasms, severe osteoarthritis, migraines |
| Other drugs taken: | | Klonopin, Ultram | | |
Reported Results |
| Benefits: | | None |
| Side effects: | | Extreme swelling of face, hands and feet, as well as, raised welts on skin |
| Comments: | | Patient was being weened off of 3600mg/day of Neurontin on to Lyrica. As the dosage taken of Neurontin lessened and that of Lyrica increased so did the side effects. Patient was taken totally off of Lyrica and, successfully, placed back on Neurontin. |
|
|
|
Page last updated: 2012-05-11
|
